Back
Alaris Equity Partners Income Trust Vs. Xtacy Therapeutics Industry Stock Comparison
Buy
71
AD.UN.TO
Alaris Equity Partners Income Trust
Last Price:
16.25
Seasonality Move:
6.17%
Sell
22
XTCY.CX
Xtacy Therapeutics
Last Price:
0.03
Seasonality Move:
-11.71%
Buy
71
Alaris Equity Partners Income Trust (AD.UN.TO)
is a Buy
Is Alaris Equity Partners Income Trust a Buy, Sell or Hold?
- The current Alaris Equity Partners Income Trust [AD.UN.TO] share price is $16.25. The Score for AD.UN.TO is 71, which is 42% above its historic median score of 50, and infers lower risk than normal.
- AD.UN.TO is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
22
Xtacy Therapeutics (XTCY.CX)
is a Sell
Is Xtacy Therapeutics a Buy, Sell or Hold?
- The current Xtacy Therapeutics [XTCY.CX] share price is $0.03. The Score for XTCY.CX is 22, which is 56% below its historic median score of 50, and infers higher risk than normal.
- XTCY.CX is currently trading in the 20-30% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
AD.UN.TO Stock Price Chart
What is Alaris Equity Partners Income Trust's stock price today?
-
The Alaris Equity Partners Income Trust share price today is $16.25
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and AD.UN.TO is experiencing buying pressure, which is a positive indicator for future bullish movement.
XTCY.CX Stock Price Chart
What is Xtacy Therapeutics's stock price today?
-
The Xtacy Therapeutics share price today is $0.03
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and XTCY.CX is experiencing selling pressure, which indicates risk of future bearish movement.
AD.UN.TO Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.16 | Sell |
| Relative Strength Index (14 RSI): | 56.13 | Buy |
| Chaikin Money Flow: | 41814 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (15.56 - 16.5) | Buy |
| Bollinger Bands (100): | (15.94 - 16.76) | Sell |
XTCY.CX Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0 | Sell |
| Relative Strength Index (14 RSI): | 38.3 | Sell |
| Chaikin Money Flow: | -150000 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (0.03 - 0.05) | Sell |
| Bollinger Bands (100): | (0.04 - 0.06) | Sell |
AD.UN.TO Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 15.74 | Buy |
| 20-day SMA: | 15.87 | Buy |
| 50-day SMA: | 16.33 | Sell |
| 200-day SMA: | 15.45 | Buy |
| 8-day EMA: | 15.84 | Buy |
| 20-day EMA: | 15.93 | Buy |
| 50-day EMA: | 16.15 | Buy |
| 200-day EMA: | 15.92 | Buy |
XTCY.CX Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 0.04 | Sell |
| 20-day SMA: | 0.04 | Sell |
| 50-day SMA: | 0.05 | Sell |
| 200-day SMA: | 0.05 | Sell |
| 8-day EMA: | 0.04 | Sell |
| 20-day EMA: | 0.04 | Sell |
| 50-day EMA: | 0.05 | Sell |
| 200-day EMA: | 0.06 | Sell |
Alaris Equity Partners Income Trust Earnings Growth & AD.UN.TO Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Xtacy Therapeutics Earnings Growth & XTCY.CX Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Alaris Equity Partners Income Trust Technical Analysis
| Apr 23 | Apr 24 | Apr 25 | Apr 26 | Apr 29 | Apr 30 | May 1 | May 2 | May 3 | May 6 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | May | |||||||||
| 23 | 24 | 25 | 26 | 29 | 30 | 01 | 02 | 03 | 06 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Xtacy Therapeutics Technical Analysis
| Apr 23 | Apr 24 | Apr 25 | Apr 26 | Apr 29 | Apr 30 | May 1 | May 2 | May 3 | May 6 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Apr | May | |||||||||
| 23 | 24 | 25 | 26 | 29 | 30 | 01 | 02 | 03 | 06 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||